건강인에서 NK세포 자극 후와 T세포 자극 후 분비된 Interferon-gamma 농도의 비교
Comparison of Interferon-gamma Secretion by Stimulated NK Cells and T cells from Healthy Subjects
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Interferon-γ (IFN-γ) is an important cytokine produced by natural killer (NK) cells and T cells in response to various stimuli. The levels of IFN-γ secreted after stimulation of NK cells using a recombinant cytokine is represented as one of functions of NK cells. Recently, a method for evaluating NK cell activity in whole blood samples was developed. The levels of IFN-γ secreted after NK cell stimulation with PROMOCATM (ATGen, Korea) and T cell stimulation with phytohemagglutinin (PHA) were compared using two different commercial kits: NK Vue Gold (ATGen, Korea) and QuantiFERON- TB Gold In-Tube (Cellestis, Australia). Participants included 43 healthy individuals. Whole blood samples were incubated with either PROMOCA, a recombinant cytokine that specifically activates NK cells, or with PHA. IFN-γ levels in the supernatants were measured by ELISA. The level of IFN-γ by PROMOCA stimulation (PROMOCA IFN-γ) was more varied than that by stimulation with PHA (PHA IFN-γ) (median 1,544.4 pg/mL [ range 193.7–2,530.9] vs. median 2,470.1 pg/mL [ 2,250.1–2,874.4] P =0.0001). The median of PHA IFN-γ/PROMOCA IFN-γ ratio was 1.9 (1.1–12.4). There was a significant difference in levels of IFN-γ secreted after stimulation with PROMOCA or PHA in the healthy population.
Abstract
Interferon-γ (IFN-γ) is an important cytokine produced by natural killer (NK) cells and T cells in response to various stimuli. The levels of IFN-γ secreted after stimulation of NK cells using a recombinant cytokine is represented as one of functions of NK cells. Recently, a method for evaluating NK cell activity in whole blood samples was developed. The levels of IFN-γ secreted after NK cell stimulation with PROMOCATM (ATGen, Korea) and T cell stimulation with phytohemagglutinin (PHA) were compared using two different commercial kits: NK Vue Gold (ATGen, Korea) and QuantiFERON- TB Gold In-Tube (Cellestis, Australia). Participants included 43 healthy individuals. Whole blood samples were incubated with either PROMOCA, a recombinant cytokine that specifically activates NK cells, or with PHA. IFN-γ levels in the supernatants were measured by ELISA. The level of IFN-γ by PROMOCA stimulation (PROMOCA IFN-γ) was more varied than that by stimulation with PHA (PHA IFN-γ) (median 1,544.4 pg/mL [ range 193.7–2,530.9] vs. median 2,470.1 pg/mL [ 2,250.1–2,874.4] P =0.0001). The median of PHA IFN-γ/PROMOCA IFN-γ ratio was 1.9 (1.1–12.4). There was a significant difference in levels of IFN-γ secreted after stimulation with PROMOCA or PHA in the healthy population.
참고문헌 (22)
- Vivier E, "Innate or adaptive immunity? The example of natural killer cells", Science, 331, pp.44~49 (2011)[DOI]
- Brunner KT, "Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs", Immunology, 4, pp.181~196 (1968)
- Jang YY, "An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells", Ann Clin Lab Sci, 42, pp.42~49 (2012)
- Yamashita M, "A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by owcytometry using cryopreserved human peripheral blood mononuclear cells", Sci Rep, 6, pp.19772~ (2016)[DOI]
- Alter G, "CD107a as a functional marker for the identication of natural killer cell activity", J Immunol Methods, 294, pp.15~22 (2004)[DOI]
- Lee SB, "A high-throughput assay of NK cell activity in whole blood and its clinical application", Biochem Biophys Res Commun, 445, pp.584~590 (2014)[DOI]
- Nowell PC, "Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes", Cancer Res, 20, pp.462~466 (1960)
- Wheelock EF, "Interferon-like virus inhibitor induced in human leukocytes by phytohemagglutinin", Science, 149, pp.310~311 (1965)[DOI]
- Chilson OP, "Phaseolus vulgaris phytohaemagglutinin (PHA) binds to the human T lymphocyte antigen receptor", EMBO J, 3, pp.3239~3245 (1984)
- Billiau A, "Interferon-gamma: a historical perspective", Cytokine Growth Factor Rev, 20, pp.97~113 (2009)[DOI]
- Woo KS, "Signicance of interferon-gamma response to mitogen in serial QuantiFERON-TB Gold In-Tube assay of routine laboratory practice", Clin Chim Acta, 430, pp.79~83 (2014)[DOI]
- Lange B, "Indeterminate results of a tuberculosis-specic interferon gamma release assay in immunocompromised patients", Eur Respir J, 35, pp.1179~1182 (2010)[DOI]
- Fabre V, "High proportion of indeterminate QuantiFERON-TB Gold In-Tube results in an inpatient population is related to host factors and preanalytical steps", Open Forum Infect Dis, 1, pp.ofu088~ (2014)
- Aichelburg MC, "Prognostic value of indeterminate IFN-<TEX>${\gamma}$<", TEX> release assay results in HIV-1 infection, 2012, pp.50, 2767~2769
- Banaei N, "Interferon gamma release assays for latent tuberculosis: What are the sources of variability?", J Clin Microbiol, 54, pp.845~850 (2016)[DOI]
- De Maria A, "Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation", Proc Natl Acad Sci USA, 108, pp.728~732 (2011)[DOI]
- Imai K, "Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population", Lancet, 356, pp.1795~1799 (2000)[DOI]
- Lim YA, "Evaluation of the effectiveness of NK Vue Gold kit in patients with chronic hepatitis B", J Lab Med Qual Assur, 38, pp.151~158 (2016)[DOI]
- Hou H, "Establishing the reference intervals of NK cell functions in healthy adults", Hum Immunol, 77, pp.637~642 (2016)[DOI]
- Koo KC, "Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer", PLoS One, 8, pp.e78049~ (2013)[DOI]
- Dahlberg CI, "Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity", Front Immunol, 6, pp.605~ (2015)
- Guillerey C, "Targeting natural killer cells in cancer immunotherapy", Nat Immunol, 17, pp.1025~1036 (2016)[DOI]
